Jefferies Financial Group Increases Insulet (NASDAQ:PODD) Price Target to $400.00

Insulet (NASDAQ:PODD) had its target price hoisted by Jefferies Financial Group from $375.00 to $400.00 in a report released on Thursday, Marketbeat reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Jefferies Financial Group’s price target indicates a potential upside of 23.69% from the stock’s current price.

Other analysts have also issued reports about the stock. Stifel Nicolaus initiated coverage on shares of Insulet in a research note on Tuesday, October 21st. They set a “buy” rating and a $370.00 price target on the stock. Barclays increased their price objective on shares of Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. JPMorgan Chase & Co. raised their target price on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Finally, Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $357.42.

Insulet Trading Up 2.8%

PODD traded up $8.96 on Thursday, hitting $323.40. The company had a trading volume of 1,498,105 shares, compared to its average volume of 721,484. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm has a market cap of $22.77 billion, a P/E ratio of 98.30, a PEG ratio of 2.64 and a beta of 1.40. The company’s fifty day moving average price is $325.75 and its 200 day moving average price is $308.73. Insulet has a 1 year low of $230.05 and a 1 year high of $353.50.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s revenue was up 29.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts expect that Insulet will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is owned by corporate insiders.

Institutional Trading of Insulet

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Insulet by 0.5% during the 2nd quarter. Vanguard Group Inc. now owns 8,708,355 shares of the medical instruments supplier’s stock valued at $2,735,991,000 after acquiring an additional 39,403 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Insulet by 3.1% in the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock valued at $603,211,000 after buying an additional 58,309 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after buying an additional 297,734 shares during the period. Groupama Asset Managment boosted its holdings in Insulet by 0.4% in the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after acquiring an additional 3,759 shares during the period. Finally, Norges Bank acquired a new stake in Insulet in the second quarter valued at approximately $324,689,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.